Sanctuary Advisors LLC Buys New Stake in Catalent, Inc. (NYSE:CTLT)

Sanctuary Advisors LLC purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,728 shares of the company’s stock, valued at approximately $208,000.

Several other institutional investors have also bought and sold shares of the business. Nisa Investment Advisors LLC raised its position in shares of Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after buying an additional 185 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter. Czech National Bank raised its position in shares of Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after buying an additional 228 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Catalent by 1.4% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock valued at $1,082,000 after buying an additional 257 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Catalent by 3.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after buying an additional 278 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CTLT shares. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com started coverage on shares of Catalent in a research report on Saturday, October 12th. They issued a “hold” rating on the stock. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Nine equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent has an average rating of “Hold” and an average price target of $59.83.

Insider Activity

In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ricky Hopson sold 662 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now owns 29,974 shares in the company, valued at approximately $1,785,251.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,410 shares of company stock worth $732,680. Corporate insiders own 0.31% of the company’s stock.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $60.29 on Monday. The firm has a market cap of $10.91 billion, a PE ratio of -9.88, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. The firm’s 50 day simple moving average is $60.12 and its 200-day simple moving average is $57.79. Catalent, Inc. has a one year low of $31.80 and a one year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Catalent (NYSE:CTLT) last issued its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. The business had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, equities analysts predict that Catalent, Inc. will post 0.95 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.